Brant Inman

Overview:

Clinical research interests:
Clinical trials of novel diagnostic tests and therapies for genitourinary malignancies, with a strong focus on bladder cancer.

Basic science research interests:
Immune therapies for cancer, hyperthermia and heat-based treatment of cancer, molecular biology of genitourinary cancers, novel diagnostics and therapies for genitourinary cancers

Positions:

Cary N. Robertson, MD, Associate Professor

Surgery, Urology
School of Medicine

Associate Professor of Surgery

Surgery, Urology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

B.S. 1999

University of Alberta (Canada)

M.D. 2000

University of Alberta (Canada)

M.S. 2011

Mayo Medical School

Residency, Urology

Universite Laval (Canada)

Fellowship, Urologic Oncology

Mayo Clinic

Grants:

Phase II Trial of Aerobic Training in Metastatic Breast Cancer

Administered By
Radiation Oncology
Awarded By
National Institutes of Health
Role
Investigator
Start Date
End Date

PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY BLADDER CANCER

Administered By
Surgery, Urology
Role
Principal Investigator
Start Date
End Date

Phase 2 Study of BC-819 in Patients with Non-Muscle Invasive Bladder Cancer Whose Disease is Unresponsive to Bacillus Calmette-Guerin

Administered By
Surgery, Urology
Awarded By
Anchiano Therapeutics
Role
Principal Investigator
Start Date
End Date

Phase II open label study of Atezolizumab administered with/without BCG

Administered By
Surgery, Urology
Role
Principal Investigator
Start Date
End Date

TAR-200 Study

Administered By
Surgery, Urology
Role
Principal Investigator
Start Date
End Date

Publications:

SIPULEUCEL-T IMMUNOTHERAPY FOR CASTRATE-RESISTANT PROSTATE CANCER MODULATES SOLUBLE B7-H3: A NOVEL MECHANISM OF ACTION

MLA Citation
Chang, Andrew, et al. “SIPULEUCEL-T IMMUNOTHERAPY FOR CASTRATE-RESISTANT PROSTATE CANCER MODULATES SOLUBLE B7-H3: A NOVEL MECHANISM OF ACTION.” Journal of Urology, vol. 199, no. 4, ELSEVIER SCIENCE INC, 2018, pp. E373–E373.
URI
https://scholars.duke.edu/individual/pub1398648
Source
wos
Published In
The Journal of Urology
Volume
199
Published Date
Start Page
E373
End Page
E373

Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.

Atezolizumab (Tecentriq, MPDL3280A; Genentech/Roche) is an FcγR binding-deficient, fully humanized IgG1 mAb designed to interfere with the binding of PD-L1 ligand to its two receptors, PD-1 and B7.1. By blocking the PD-L1/PD-1 immune checkpoint, atezolizumab reduces immunosuppressive signals found within the tumor microenvironment and, consequently, increases T-cell-mediated immunity against the tumor. Atezolizumab has been FDA approved as second-line therapy for advanced bladder cancer. This accelerated approval was based on phase II trial data in patients with metastatic bladder cancer that showed unexpected and durable tumor responses. In subjects whose tumors progressed on first-line platinum-based chemotherapy, the objective response rate was 15%, the complete response rate was 5%, and 1-year overall survival was 36%. In subjects that were chemotherapy naïve and cisplatin ineligible, the objective response rate was 24%, the complete response rate was 7%, and 1-year overall survival was 57%. Better responses were associated with higher PD-L1 expression on the tumor-infiltrating leukocytes. These data suggest that patients with advanced bladder cancer treated with atezolizumab have significantly better response rates and survival than historical controls treated with other second-line regimens. The toxicity profile of atezolizumab is also favorable. Trials are currently assessing whether atezolizumab is effective in earlier bladder cancer stages and in the first-line metastatic setting. Clin Cancer Res; 23(8); 1886-90. ©2016 AACR.
Authors
Inman, BA; Longo, TA; Ramalingam, S; Harrison, MR
MLA Citation
Inman, Brant A., et al. “Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer..” Clin Cancer Res, vol. 23, no. 8, Apr. 2017, pp. 1886–90. Pubmed, doi:10.1158/1078-0432.CCR-16-1417.
URI
https://scholars.duke.edu/individual/pub1161868
PMID
27903674
Source
pubmed
Published In
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Volume
23
Published Date
Start Page
1886
End Page
1890
DOI
10.1158/1078-0432.CCR-16-1417

MP01-08 NO DIFFERENCE IN PHYSICAL ACTIVITY IN BLADDER CANCER SURVIVORS TREATED WITH TRANSURETHRAL RESECTION OR RADICAL CYSTECTOMY.

Authors
Fantony, J; Gopalakrishna, A; Longo, T; Inman, B
MLA Citation
Fantony, Joseph, et al. “MP01-08 NO DIFFERENCE IN PHYSICAL ACTIVITY IN BLADDER CANCER SURVIVORS TREATED WITH TRANSURETHRAL RESECTION OR RADICAL CYSTECTOMY..” Journal of Urology, vol. 195, no. 4S, Ovid Technologies (Wolters Kluwer Health), 2016. Crossref, doi:10.1016/j.juro.2016.02.1838.
URI
https://scholars.duke.edu/individual/pub1398659
Source
crossref
Published In
The Journal of Urology
Volume
195
Published Date
DOI
10.1016/j.juro.2016.02.1838

A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer.

PURPOSE: Ths paper reports a pilot/feasibility trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) prior to transurethral resection of bladder tumour (TURBT) for non-muscle invasive bladder cancer (NMIBC). MATERIALS AND METHODS: A pilot/feasibility clinical trial was performed and 15 patients with intermediate to high-risk NMIBC received HIVEC prior to TURBT. HIVEC consisting of eight weekly instillations of intravesical MMC (80 mg in 50 mL) delivered with the novel Combat BRS® system at a temperature of 43 °C for 60 min. Treatment-related adverse effects were measured and patients were followed for 2 years for disease recurrence. RESULTS: A total of 119 HIVEC treatments occurred. Grade 1 adverse events consisted of irritative bladder symptoms (33%), bladder spasms (27%), pain (27%), haematuria (20%) and urinary tract infection (UTI; 14%). Grade 2 adverse events were bladder calcification (7%) and reduced bladder capacity (7%). No grade 3 or higher toxicity was observed. At TURBT, eight patients (53%) were complete responders (pT0) while seven (47%) were partial responders. With a median follow-up of 29 months, the 3-year cumulative incidence of recurrence was 15%. CONCLUSIONS: The Combat BRS® system achieved target bladder temperatures and delivered HIVEC with a favourable side-effect profile. Our pilot trial also provides preliminary evidence of treatment efficacy.
Authors
Sousa, A; Inman, BA; Piñeiro, I; Monserrat, V; Pérez, A; Aparici, V; Gómez, I; Neira, P; Uribarri, C
MLA Citation
Sousa, Alejandro, et al. “A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer..” Int J Hyperthermia, vol. 30, no. 3, May 2014, pp. 166–70. Pubmed, doi:10.3109/02656736.2014.900194.
URI
https://scholars.duke.edu/individual/pub1031362
PMID
24697672
Source
pubmed
Published In
Int J Hyperthermia
Volume
30
Published Date
Start Page
166
End Page
170
DOI
10.3109/02656736.2014.900194

Abstract 1376: Exercise alters breast cancer phenotype through distinct reductions in host-derived proinflammatory growth factor ligands.

Authors
Glass, O; Inman, BA; Courneya, KS; Mackey, JR; Nelson, E; Hartman, Z; Jones, LW
MLA Citation
Glass, Oliver, et al. “Abstract 1376: Exercise alters breast cancer phenotype through distinct reductions in host-derived proinflammatory growth factor ligands..” Clinical Research, American Association for Cancer Research, 2013. Crossref, doi:10.1158/1538-7445.am2013-1376.
URI
https://scholars.duke.edu/individual/pub1025046
Source
crossref
Published In
Clinical Research
Published Date
DOI
10.1158/1538-7445.am2013-1376

Research Areas:

BCG Vaccine
Cancer Vaccines
Carcinoma, Renal Cell
Clinical Trial
Cystectomy
Immunotherapy
Immunotherapy, Adoptive
Kidney Neoplasms
Magnetic nanoparticle hyperthermia
Metastasectomy
Nephrectomy
Penile Neoplasms
Prostate
Prostatic Neoplasms
Thermotherapy
Urethral Neoplasms
Urinary Bladder Neoplasms
Urinary Diversion
Urologic Neoplasms
Urology